twentyseven
year
discoveri
hiv
caus
aid
drug
direct
four
differ
viral
target
ie
revers
transcriptas
proteas
integras
envelop
one
cellular
target
ie
coreceptor
avail
treatment
howev
search
effici
vaccin
still
ongo
one
main
problem
presenc
continu
evolv
dens
carbohydr
shield
consist
nlink
glycan
surround
virion
protect
effici
recognit
persist
neutral
immun
system
howev
sever
lectin
innat
immun
system
specif
bind
glycan
attempt
process
viru
antigen
provok
immun
respons
across
wide
varieti
differ
speci
natur
lectin
found
interact
glycosyl
envelop
block
infect
suscept
cell
viru
review
give
overview
lectin
nonmammalian
origin
endow
antivir
properti
discuss
complex
interact
lectin
innat
immun
system
also
attent
given
differ
carbohydraterel
modal
exploit
antivir
chemotherapi
varieti
envelop
virus
also
contain
highli
glycosyl
envelop
protein
thu
may
target
cba
hcv
envelop
rna
viru
classifi
within
famili
flavivirida
infect
hcv
often
lead
chronic
diseas
hepat
cirrhosi
hepatocellular
carcinoma
major
site
replic
liver
cell
type
monocyt
macrophag
also
report
becom
infect
hcv
four
cellular
receptor
alreadi
identifi
requir
time
hcventri
occur
hcv
encod
two
envelop
glycoprotein
review
contain
six
potenti
nglycosyl
site
contain
nglycan
howev
due
prolin
immedi
downstream
consensu
sequenc
one
potenti
nglycosyl
site
recogn
oligosaccharyltransferas
potenti
glycosyl
motif
occupi
highmannos
type
glycan
except
posit
complex
type
glycan
found
thought
glycoprotein
respons
initi
viru
attach
glycoprotein
respons
fusion
viru
cell
membran
denv
singl
positivestrand
rna
viru
also
belong
flavivirida
famili
transmit
aed
aegypti
mosquito
infect
result
flulik
symptom
progress
dengu
hemorrhag
fever
caus
death
half
million
patient
hospit
year
two
glycoprotein
found
surfac
immatur
viru
particl
premembran
prm
envelop
e
protein
review
upon
matur
viru
particl
prm
cleav
envelop
e
protein
form
shell
viru
chang
conform
immatur
matur
fusionactiv
state
virion
review
refer
therein
contrast
member
flavivirida
famili
e
glycoprotein
denv
contain
nlink
glycosyl
site
conserv
among
flavivirus
uniqu
denv
postul
nlink
glycan
posit
highmannos
type
oligosaccharid
posit
paucimannos
type
glycan
type
abundantli
found
insect
cell
glycan
also
plant
coronavirus
given
renew
interest
discoveri
sever
acut
respiratori
syndrom
sar
caus
coronaviru
sarscov
coronavirus
envelop
singlestrand
posit
rna
virus
review
sever
coronavirus
import
veterinari
pathogen
caus
respiratori
enter
diseas
livestock
poultri
envelop
consist
membran
protein
spike
protein
envelop
protein
e
e
protein
glycosyl
protein
glycoprotein
nlink
glycan
posit
main
structur
compon
virion
mediat
assembl
bud
viral
particl
spike
protein
form
trimer
belong
group
class
viral
fusion
protein
also
includ
env
mediat
viruscel
attach
fusion
protein
cleav
proteas
like
trypsin
factor
xa
subunit
spike
protein
sarscov
heavili
glycosyl
put
nglycosyl
site
least
describ
glycosyl
four
oligosaccharid
structur
determin
two
highmannos
type
two
complex
type
coronavirus
includ
felin
infecti
periton
viru
fipv
mous
hepat
viru
mhv
felin
enter
coronaviru
fecv
recent
outbreak
influenza
also
known
swine
flu
avian
flu
rais
need
better
understand
influenza
viru
infect
block
influenza
type
virus
categor
base
properti
two
membran
glycoprotein
spike
hemagglutinin
ha
neuraminidas
na
date
differ
ha
differ
na
variant
known
differ
viru
subtyp
amino
acid
sequenc
ha
vari
ha
play
major
role
influenza
lectin
carbohydratebind
protein
modifi
carbohydr
bind
protein
found
across
wide
varieti
differ
speci
natur
includ
prokaryot
sea
coral
alga
fungi
higher
plant
invertebr
vertebr
also
synthet
agent
carbohydratebind
capac
identifi
term
carbohydratebind
agent
cba
introduc
includ
peptid
lectin
nonpeptid
lowmolecularweight
agent
bind
cba
nlink
glycan
glycoprotein
predominantli
occur
via
mannos
glucos
fucos
nacetylglucosamin
galactos
nacetylgalactosamin
andor
sialic
acid
residu
intern
linkag
individu
monosaccharid
nlink
glycan
play
import
role
specif
bind
cba
human
immun
system
take
advantag
presenc
dens
glycan
shield
surround
certain
pathogen
variou
ctype
lectin
dcsign
dendrit
cell
dc
mannos
receptor
mmr
macrophag
solubl
mannosebind
lectin
mbl
found
plasma
sever
bind
oligosaccharid
surfac
virus
bacteria
order
remov
case
antigenpres
cell
present
foreign
epitop
cell
provok
effici
immun
respons
pathogen
howev
discuss
review
pathogen
tri
circumv
erad
use
ctype
lectin
innat
immun
system
gain
easili
access
lymph
node
popul
lymphocyt
recent
cba
put
spotlight
new
potenti
promis
antivir
agent
sinc
discoveri
infect
heavili
glycosyl
virus
human
immunodefici
viru
review
see
hepat
c
viru
hcv
could
effici
block
certain
cba
moreov
cba
prevent
viru
entri
target
host
cell
longterm
drug
pressur
result
select
viru
strain
sever
nlink
glycan
constitut
protect
glycan
shield
around
viral
particl
delet
shield
mask
import
immunogen
epitop
viral
envelop
often
protect
viru
recognit
erad
neutral
antibodi
immun
system
cba
might
potenti
assist
immun
system
contain
viral
infect
dual
mode
action
might
also
work
glycancontain
envelop
virus
case
flavivirus
dengu
viru
denv
coronavirus
like
sever
acut
respiratori
syndrom
coronaviru
sarscov
nidoviral
thu
cba
becom
effici
antivir
compound
need
abl
inhibit
specif
interact
virus
lectin
immun
system
use
viru
transmiss
establish
infect
review
overview
given
cba
abl
bind
neutral
hiv
predominantli
includ
lectin
prokaryot
plant
origin
semi
synthet
cba
also
lectin
immun
system
cba
concept
treatment
glycosyl
envelop
virus
thoroughli
cover
recent
advanc
emerg
field
discuss
envelop
consist
highli
glycosyl
surfac
protein
transmembran
protein
first
bind
cellular
receptor
undergo
conform
chang
bind
coreceptor
bind
trigger
conform
chang
result
insert
fusion
peptid
cellular
membran
eventu
fusion
viru
cell
around
averag
nglycosyl
motif
nxt
x
prolin
found
sequenc
shown
leonard
et
al
motif
occupi
glycan
moreov
oligosaccharid
determin
highmannos
type
hybrid
type
complex
type
remark
ratio
favor
highmannos
type
glycan
virus
deriv
glycan
glycosyl
machineri
host
cell
high
densiti
highmannos
type
glycan
never
observ
mammalian
glycoprotein
therefor
might
expect
neutral
mannosespecif
lectin
innat
immun
system
mbl
opposit
true
discuss
review
host
lectin
bind
hiv
presum
highmannos
type
glycan
hiv
use
event
surviv
escap
destruct
immun
system
viru
entri
bind
ha
termin
sialic
acid
epitheli
receptor
viru
taken
endocytosi
low
ph
endosom
activ
fusion
viral
endosom
membran
review
ha
synthes
precursor
cleav
gener
glycosyl
among
subtyp
variat
glycosyl
extens
glycosyl
conserv
intens
studi
oligosaccharid
ha
fowl
plagu
viru
suggest
presenc
seven
nlink
glycan
five
complex
type
one
prove
highmannos
type
one
hybrid
type
howev
number
structur
glycan
vari
greatli
among
differ
influenza
subtyp
even
viru
evolut
time
human
cell
lymphotrop
viru
type
first
human
retroviru
associ
diseas
like
adult
cell
leukemia
atl
cutan
cell
lymphoma
htlvassoci
myelopathi
ham
surfac
unit
noncoval
attach
membran
unit
build
envelop
contain
five
glycosyl
motif
util
contain
one
nglycan
motif
doublestrand
dna
virus
constitut
herp
simplex
viru
famili
herp
simplex
viru
hsv
type
type
member
alphaherpesviru
subfamili
five
glycoprotein
involv
hsv
entri
gb
gc
gd
gh
gl
glycoprotein
also
play
role
immun
evas
cellular
respons
gc
famili
type
membran
glycoprotein
contain
nlink
least
eight
potenti
nglycan
site
olink
mucinlik
glycan
also
human
cytomegaloviru
cmv
contain
sever
glycoprotein
envelop
ie
nlink
highmannos
type
carbohydr
determin
sever
virus
contain
glycoprotein
envelop
ie
parainfluenza
virus
respiratori
syncyti
viru
etc
consid
review
due
report
insensit
cba
lack
report
literatur
potenti
interact
cba
sever
lectin
prokaryot
origin
shown
abl
bind
carbohydratedepend
manner
intens
studi
prokaryot
antivir
lectin
cyanovirinn
cvn
deriv
cyanobacterium
nostoc
ellipsosporum
kda
small
virucid
protein
abl
inactiv
divers
laboratori
hivstrain
primari
isol
well
siv
strain
nanomolar
concentr
crystal
structur
reveal
cvn
form
dimer
domain
swap
therebi
creat
two
new
carbohydratebind
site
besid
two
primari
bind
site
cvn
preferenti
bind
glycan
contain
present
termin
branch
highmannos
type
glycan
besid
cvn
also
report
inhibit
infect
hcv
influenza
viru
ebola
viru
hsv
infect
cell
cultur
microbicid
potenti
cvn
alreadi
proven
macaqu
model
attempt
construct
live
microbicid
engin
lactobacillu
strain
express
cvn
way
howev
care
taken
consid
cvn
potenti
microbicid
shown
recent
lectin
induc
express
wide
panel
chemokin
stimulatorymitogen
activ
pbmc
cultur
might
result
cell
suscept
hivinfect
induct
replic
latent
infect
cell
three
lectin
deriv
cyanobacteria
describ
possess
antihivact
mvl
deriv
microcysti
viridi
mannanbind
lectin
kda
compos
two
tandemli
repeat
homolog
domain
amino
acid
minim
target
compris
tetrasaccharid
core
oligomannosid
scytovirin
express
scytonema
varium
consist
amino
acid
organ
two
domain
carbohydratebind
site
five
intrachain
disulfid
brigd
bind
interact
tetramannosid
unit
oligosaccharid
final
new
lectin
filament
cyanobacterium
oscillatoria
agardhii
oaa
describ
endow
antivir
activ
oaa
exclus
bind
highmannos
type
nglycan
alik
scytovirin
oaa
possess
two
carbohydratebind
site
per
molecul
abl
inhibit
infect
concentr
nanomolar
rang
carbohydratebind
protein
deriv
sea
coral
gerardia
savaglia
one
first
lectin
shown
possess
antihiv
activ
cell
cultur
kda
protein
consist
dimer
requir
ca
effici
carbohydr
bind
show
specif
dmannos
actinomycet
strain
also
known
longispora
albida
actinohivin
ah
deriv
ah
molecular
mass
kda
exhibit
intern
sequenc
triplic
like
cba
antivir
properti
ah
inhibit
viral
entri
bind
highmannos
type
glycan
recent
crystal
structur
ah
resolv
reveal
threedimension
structur
contain
three
sugarbind
pocket
fig
thu
case
cba
describ
far
one
go
describ
multival
seem
common
among
mani
natur
deriv
cba
griffithsin
grft
extract
red
alga
griffithsia
sp
one
potent
antihiv
cba
describ
far
abl
block
infect
picomolar
rang
reason
grft
studi
potenti
candid
microbicid
agent
determin
structur
reveal
grft
consist
domainswap
dimer
monom
three
almost
ident
carbohydratebind
site
fig
sinc
late
antivir
research
also
focus
potenti
plant
lectin
antivir
agent
plant
lectin
isol
thousand
plant
speci
well
document
review
see
plant
lectin
antivir
activ
mention
brief
plant
lectin
antihiv
activ
specif
mannos
mannosespecif
plant
lectin
cha
cymbidium
hybrid
agglutinin
eha
epipacti
helleborin
agglutinin
loa
listera
ovata
agglutinin
npa
narcissu
pseudonarcissu
agglutinin
gna
galanthu
nivali
agglutinin
hha
hippeastrum
hybrid
agglutinin
potent
inhibitor
entri
target
cell
also
nacetylglucosaminespecif
lectin
sting
nettl
urtica
dioica
uda
kda
size
among
smallest
lectin
known
far
abl
prevent
hiv
infect
fig
myrianthu
holstii
like
uda
small
cysteinerich
lectin
glcnac
specif
activ
hiv
nanomolar
concentr
varieti
plantderiv
lectin
includ
mannosespecif
lectin
allium
porrum
apa
allium
ursinum
aua
mannosespecif
lectin
fabacea
famili
pea
bean
show
antihiv
activ
cell
cultur
tabl
recent
new
plant
lectin
deriv
banana
musa
acuminata
name
banlec
describ
inhibit
infect
bind
highmannos
type
glycan
concanavalin
cona
wheat
germ
agglutinin
wga
phytohaemagglutinin
pha
also
seem
recogn
carbohydr
hiv
show
antihiv
activ
rather
cytotox
ie
mitogen
cell
cultur
three
lectin
isol
annelida
famili
also
report
possess
antihiv
activ
lectin
cvl
isol
marin
worm
chaetopteru
variopedatu
lectin
known
far
inhibit
bind
bgalactos
glcnacspecif
ca
independ
lectin
isol
sea
worm
serpula
vermiculari
svl
homotetramer
protein
total
molecular
mass
kda
final
mermaid
purifi
laxu
oneistu
ca
depend
mannosespecif
lectin
structur
homolog
dcsign
abl
inhibit
bind
dcsign
mammal
proteincarbohyd
interact
serv
multipl
function
innat
immun
system
play
dual
role
involv
varieti
cellcel
interact
function
well
pathogen
recognit
may
lead
pathogen
neutral
three
major
structur
famili
vertebr
lectin
exist
galectin
siglec
ctype
lectin
extens
overview
lectin
immun
system
scope
review
mainli
focu
lectin
report
andor
potenti
abl
interact
includ
subset
ctype
lectin
also
carbohydratespecif
antibodi
minidefensin
tabl
ii
galectin
famili
solubl
lectin
design
galactos
specif
galectin
discov
far
report
interact
promot
viral
adsorpt
presenc
viru
infect
increas
increas
could
block
lactos
suggest
involv
carbohydraterecognit
domain
crd
siglec
sialic
acidbind
iglik
lectin
constitut
distinct
subset
ig
superfamili
name
suggest
glycanbind
protein
well
known
specif
sialic
acidcontain
glycan
nacetylneuramin
acid
common
sialoadhesin
express
activ
macrophag
chronic
inflamm
tumor
also
monocyt
infect
individu
express
sialoadhesin
upregul
cell
infect
circul
sialoadhesinexpress
monocyt
capabl
bind
expos
viru
immun
target
cell
vertebr
lectin
member
ctype
ca
depend
lectin
famili
also
call
ctype
lectin
receptor
clr
fact
protein
contain
one
ctype
lectin
domain
classifi
clr
ctype
lectin
either
produc
transmembran
protein
secret
solubl
protein
review
ref
solubl
lectin
includ
member
collectin
famili
mannosebind
protein
mbp
lung
surfact
protein
spa
spd
base
molecular
structur
two
group
ctype
lectin
distinguish
dc
type
ctype
lectin
extracellular
nterminu
ie
mmr
type
ii
lectin
intracellular
nterminu
ie
dcsign
lsign
langerin
type
ii
ctype
lectin
contain
one
crd
type
lectin
contain
sever
crd
crdlike
domain
dcsign
lsign
dcsign
stand
dcspecif
grab
nonintegrin
first
ctype
lectin
shown
abl
bind
siv
enhanc
tran
infect
cell
type
ii
integr
membran
protein
amino
acid
ectodomain
contain
short
ntermin
domain
repeat
region
consist
copi
amino
acid
sequenc
ctermin
crd
form
tetram
present
cellular
membran
structur
studi
feinberg
et
al
reveal
crd
dcsign
interact
intern
mannos
present
highmannos
type
glycan
later
appelmelk
et
al
discov
dcsign
bind
also
lewi
blood
group
antigen
contain
fucos
residu
moreov
dcsign
bind
much
higher
affin
fucosecontain
carbohydr
le
x
mannotrios
thu
dcsign
effici
recogn
least
two
class
glycan
mannoserich
glycan
fucosyl
glycan
dcsign
name
suggest
found
subset
immatur
dendrit
cell
imdc
later
shown
also
express
surfac
macrophag
placenta
lung
subset
b
cell
peripher
blood
tonsil
healthi
seroneg
donor
lectin
involv
interact
dc
rest
cell
interact
imdc
peripher
tissu
captur
antigen
subsequ
migrat
cell
area
secondari
lymphoid
organ
journey
lymphoid
organ
express
profil
chang
downmodul
express
dcsign
upregul
express
chemokin
receptor
cell
surfac
molecul
lymph
node
matur
dc
abl
activ
rest
cell
instead
taken
dc
degrad
lysosom
compart
hiv
bind
dcsign
use
dcsign
afford
infect
cell
lymphoid
tissu
mention
time
dcsign
discov
also
shown
abl
bind
dcsign
transfer
rest
cell
lymphoid
tissu
process
name
tran
infect
cell
shown
baribaud
et
al
product
infect
pbmc
hiv
could
occur
viru
amount
suffici
initi
infect
appli
directli
activ
cell
free
viru
particl
thu
hiv
attach
dc
dcsign
effici
transmit
lymphocyt
cellfre
viru
moreov
hiv
bound
dcsign
remain
infecti
day
due
intern
intact
hiv
nonlysosom
compart
howev
viru
save
degrad
probabl
minor
intern
viru
retain
kept
intact
insid
dc
major
viru
particl
degrad
process
present
lymphocyt
lymph
node
dc
also
express
although
express
level
low
support
effici
hivinfect
howev
dcsign
abl
concentr
hiv
surfac
dc
thu
facilit
interact
enhanc
infect
ci
fact
shown
dcsign
surfac
level
upregul
hivinfect
cell
caus
hiv
protein
nef
act
inhibit
dcsign
endocytosi
upregul
dramat
increas
interact
dc
lymphocyt
transmiss
thu
dc
transfer
lymphocyt
two
distinct
phase
first
phase
viru
intern
nonlysosom
compart
transfer
via
infecti
synaps
lymphocyt
within
hr
howev
time
dc
becom
infect
complex
repres
second
phase
depend
product
infect
immatur
dc
viru
inhibit
zidovudin
macrophag
present
breast
milk
induc
express
dcsign
transmit
viru
cell
howev
children
breast
fed
first
month
live
protect
hiv
infect
recent
shown
number
factor
present
human
breast
milk
block
dcsignmedi
hiv
transmiss
cell
thu
inhibit
mothertochild
transmiss
first
report
multimer
proteinassoci
lewi
x
le
x
motif
breast
milk
could
bind
dcsign
prevent
captur
subsequ
transmiss
lymphocyt
later
also
bile
saltstimul
lipas
le
x
contain
glycoprotein
abundantli
present
breast
milk
also
report
inhibit
bind
dcsign
moreov
iga
igg
antibodi
dcsign
crd
also
abl
bind
dcsign
inhibit
transmiss
tran
thu
although
transmit
via
breast
milk
factor
present
breast
milk
suppress
mothertochild
transmiss
lsign
previous
name
dcsignr
dcsign
homologu
also
describ
abl
captur
siv
transmit
viru
human
pbmc
exhibit
amino
acid
ident
dcsign
receptor
express
sinusoid
endotheli
cell
liver
endotheli
cell
lymph
node
sinus
placent
villi
lymph
node
repres
major
site
hiv
replic
vivo
presenc
lsign
surfac
endotheli
cell
lymph
node
sinus
repres
obviou
mechan
viru
transmit
cell
dcsign
captur
also
mani
virus
contain
glycosyl
envelop
cmv
express
envelop
glycoprotein
gb
bind
dcsign
transmit
permiss
cell
also
case
hcv
lsign
dcsign
captur
transmit
viru
hepatocyt
sarscov
lectin
receptor
also
bind
ebola
viru
gp
act
cofactor
cellular
entri
dcsignbound
ebola
viru
could
also
transmit
suscept
cell
infect
marburg
viru
greatli
enhanc
dcsign
lsign
express
denv
use
dcsign
product
infect
dc
final
also
abl
bind
dcsign
via
glycoprotein
moreov
presenc
dcsign
significantli
enhanc
viral
entri
suscept
cell
like
bound
dcsign
transmit
cell
howev
presenc
highli
glycosyl
envelop
necessarili
impli
bind
viru
dcsign
occur
exampl
vesicular
stomat
viru
contain
highli
glycosyl
envelop
interact
dcsign
observ
indic
degre
select
exist
recognit
glycoprotein
dcor
lsign
b
langerin
langerhan
cell
lc
imdc
locat
skin
epidermi
mucos
tissu
express
uniqu
type
ii
transmembran
receptor
langerin
like
dc
lc
perform
essenti
function
immun
respons
abil
take
process
foreign
well
self
antigen
present
process
antigen
cell
migrat
lymph
node
present
stratifi
squamou
epithelia
genit
mucosa
probabl
among
first
cell
encount
hiv
sexual
transmiss
extracellular
region
receptor
exist
trimer
crd
show
specif
mannos
glcnac
fucos
crd
langerin
resembl
crd
ctype
lectin
except
sever
extra
secondari
structur
element
langerin
addit
helix
new
twostrand
bsheet
langerin
possess
one
four
possibl
calciumbind
site
describ
fold
appear
second
calciumindepend
sugarbind
site
crd
kawamura
et
al
report
immatur
lc
product
infect
hiv
preincub
lc
mannan
egta
known
inhibitor
ctype
lectin
bind
block
infect
conclud
lc
infect
hiv
sole
depend
presenc
cell
membran
howev
function
langerin
hiv
infect
transmiss
seem
complex
initi
thought
contrast
ctype
lectin
like
dcsign
mannos
receptor
mr
langerin
shown
prevent
transmiss
lc
inde
captur
langerin
intern
birbeck
granul
degrad
langerin
block
antibodi
protect
function
hiv
infect
disappear
stori
becam
complic
fahrback
et
al
discov
lc
activ
lp
tnfa
could
effici
mediat
transinfect
activ
lc
appar
led
downregul
cell
surfac
langerin
express
transmiss
rate
hiv
sexual
intercours
low
maletofemal
transmiss
probabl
semen
per
exposur
genit
tract
multilay
barrier
invad
pathogen
first
layer
consist
mucu
trap
pathogen
prevent
infect
next
layer
stratifi
squamou
epithelium
lc
resid
howev
hiv
reach
epithelium
physic
breach
epitheli
integr
need
pathogen
lp
outer
membran
physic
trauma
often
associ
tnfa
product
caus
lesion
epithelium
hiv
would
cross
epithelium
circumst
lc
would
probabl
activ
captur
transfer
viru
cell
mmr
type
transmembran
protein
found
macrophag
dc
mediat
phagocytosi
endocytosi
pinocytosi
antigen
contain
mannos
fucos
nacetylglucosamin
glucos
target
lysosom
proteolyt
degrad
present
major
histocompat
complex
ii
receptor
consist
five
domain
cysteinerich
amino
terminu
homolog
ricin
b
chain
fibronectin
type
ii
repeat
region
eight
calciumdepend
crd
homolog
transmembran
region
cytoplasm
domain
like
dcsign
mmr
abl
bind
ca
depend
manner
transmit
viru
target
cell
import
differ
two
receptor
first
mmr
oligomeris
dimer
dcsign
form
tetram
fact
hiv
bind
dimer
mmr
second
bind
mmr
block
egta
point
nonca
depend
bind
mmr
inde
postul
abl
bind
crd
mmr
bind
ca
depend
final
bind
mmr
induc
phagocytosi
result
viral
replic
thu
macrophag
two
independ
pathway
hiv
entri
may
coexist
pathway
infecti
rout
complex
pathway
noninfecti
phagocyt
rout
mediat
mmr
mannosebind
lectin
mbl
also
design
mannanbind
lectin
mbp
serum
protein
hepat
origin
bind
carbohydr
present
microorgan
play
role
clearanc
destruct
complement
activ
induc
opson
part
collectin
famili
compos
larg
homooligom
contain
collagen
ntermin
segment
ctermin
ctype
crd
mbl
organ
bouquet
contain
two
six
build
block
consist
trimer
constitu
polypeptid
crd
mbl
contain
two
ca
ion
specif
dmannos
nacetylglucosamin
fucos
howev
recogn
mannos
differ
way
compar
dcsign
lsign
although
crd
share
homolog
trimer
conform
crd
mbl
apart
spectroscop
modelbuild
studi
shown
termin
mannos
residu
vertebr
highmannos
glycan
apart
therefor
bind
site
mbl
far
apart
bind
vertebr
highmannos
type
glycan
optim
distanc
bind
wide
space
residu
found
surfac
bacteri
fungal
cell
way
mbl
mediat
complementmedi
lysi
opson
reaction
host
cell
contrast
dcsign
lsign
may
recogn
multipl
selfoligosaccharid
specif
arrang
surfac
certain
glycoprotein
import
toler
toward
selfantigen
earli
mbl
describ
inhibit
hiv
infect
vitro
later
saifuddin
et
al
show
primari
isol
also
interact
mbl
interact
occur
crd
mbl
addit
mannan
block
bind
result
contradict
ying
et
al
demonstr
mbl
bind
could
detect
neutral
hiv
mbl
concentr
approxim
ten
time
higher
physiolog
serum
mbl
level
howev
mbl
could
effici
opson
primari
isol
hiv
uptak
monocyt
cell
activ
classic
complement
pathway
e
lung
surfact
protein
spd
spa
anoth
member
collectin
famili
pulmonari
surfact
protein
although
organ
differ
instead
bouquet
form
cruciform
consist
four
associ
trimer
unit
spd
present
lung
also
variou
mucos
locat
blood
alik
mbl
spd
abl
bind
ca
depend
manner
albeit
signific
lower
concentr
mbl
besid
spd
anoth
pulmonari
surfact
spa
exist
compar
structur
mbl
spa
found
lung
amniot
fluid
importantli
vagin
fluid
femal
genitourinari
tract
like
mbl
spd
spa
bind
hiv
target
highmannos
glycan
envelop
calciumdepend
manner
howev
spa
also
enhanc
bind
dc
transfer
hiv
cell
f
dendrit
cell
immunoreceptor
dcir
recent
new
clr
dc
describ
attach
factor
dcir
prototyp
dcassoci
clr
downregul
upon
matur
dc
far
ligand
dcir
identifi
vivo
function
remain
elus
variou
antigenpres
cell
express
dcir
includ
b
cell
monocyt
myeloid
dc
plasmacytoid
dc
compar
dcsign
dcir
abl
captur
promot
infect
tran
ci
dcir
fourth
ctype
lectin
found
dc
besid
dcsign
langerin
mmr
thought
uniqu
clr
fulli
respons
attach
dc
subset
therefor
microbicid
design
inhibit
interact
dc
preferenti
block
possibl
clr
present
dc
g
neutral
antibodi
antibodi
uniqu
sever
way
first
antibodi
abl
bind
epitop
hiv
consist
nlink
glycan
discoveri
antibodi
direct
oligosaccharid
surpris
glycoprotein
poor
immunogen
sever
reason
one
thing
carbohydr
exhibit
microheterogen
mean
one
glycoprotein
exist
multipl
glycoform
second
glycan
dynam
structur
cover
substanti
area
amino
acid
abl
cover
potenti
epitop
protein
third
mani
virus
use
host
glycosyl
machineri
glycosyl
envelop
glycoprotein
host
recogn
structur
self
foreign
sitedirect
mutagenesi
studi
implic
epitop
consist
residu
nlink
oligosaccharid
amino
acid
posit
glycan
posit
play
indirect
role
conserv
epitop
conform
howev
structur
indic
rather
bind
amino
acid
posit
glycan
posit
may
play
indirect
role
bind
prevent
process
glycan
posit
maintain
oligmannos
structur
one
recogn
peculiar
structur
two
fab
molecul
form
dimer
swap
v
h
domain
achiev
twist
variabl
region
respect
constant
region
compar
standard
orient
fab
fig
domain
swap
result
creation
multipl
bind
site
two
correspond
normal
antibodi
two
new
site
within
v
h
v
h
interfac
base
structur
lot
initi
undertaken
design
new
immunogen
elicit
antibodi
howev
case
elicit
antibodi
abl
neutral
defensin
famili
cysteinerich
cation
antimicrobi
peptid
express
leukocyt
epitheli
cell
three
subfamili
distinguish
b
ydefensin
deriv
ancestr
gene
exist
reptil
bird
diverg
aand
bdefensin
wide
distribut
among
mammalian
studi
detail
see
review
ydefensin
also
call
minidefensin
smallest
cyclic
peptid
anim
origin
known
far
residu
big
deriv
two
precursor
peptid
contribut
nine
residu
matur
peptid
three
rhesu
monkey
ydefensin
first
discov
becam
clear
human
bone
marrow
also
express
mrna
homolog
precursor
rhesu
monkey
circular
minidefensin
howev
stop
codon
signal
sequenc
silenc
transcript
base
sequenc
human
gene
put
ancestr
human
circular
minidefensin
synthes
call
retrocyclin
retrocyclin
could
protect
human
cell
infect
vitro
base
spr
experi
conclud
retrocyclin
bind
glycosyl
suggest
lectin
later
also
human
adefensin
shown
bind
glycosyl
howev
retrocyclin
shown
bind
noncarbohydr
manner
inhibit
format
bundl
fusion
make
fusion
inhibitor
shown
adefensin
dramat
downregul
express
cell
surfac
therefor
adefensin
inhibit
interact
final
bdefensin
also
abl
inhibit
antivir
mode
potentialof
carbohydratebind
agent
k
medicin
research
review
doi
action
base
modul
coreceptor
lectinlik
properti
attribut
defensin
semi
synthet
smallsiz
nonpeptid
cba
far
lectin
natur
origin
protein
discuss
potenti
candid
antihiv
microbicid
size
protein
antigen
properti
peptid
natur
sensit
proteas
problem
associ
largescal
product
purif
make
less
qualifi
system
use
synthet
compound
lectinlik
properti
would
gentl
solut
problem
synthesi
varieti
synthet
cba
well
document
literatur
far
coupl
semi
synthet
compound
describ
endow
antivir
ie
hiv
activ
belong
pradimicinbenanomicin
antibiot
famili
antifung
compound
benzo
naphtacenequinon
contain
dalanin
monosaccharid
disaccharid
side
chain
benanomicin
b
discov
ferment
actinomadura
sp
pradimicin
ae
produc
actinomadura
hibisca
overal
pradimicin
nearli
ident
benanomicin
fig
antifung
mode
action
probabl
base
capac
bind
mannan
ca
depend
manner
two
molecul
prma
interact
one
atom
ca
creat
multipl
bind
site
interact
late
benanomicin
b
pradimicin
prma
describ
possess
antihivact
antivir
properti
prma
later
studi
detail
shown
prma
abl
inhibit
infect
nontox
concentr
prevent
viral
entri
strain
select
increas
pressur
prma
contain
eight
differ
glycan
delet
envelop
major
highmannos
type
glycan
point
highli
select
bind
antibiot
highmannos
type
glycan
envelop
prma
prove
poorli
solubl
problem
overcom
discoveri
prm
cyclic
backbon
prma
neg
charg
sulfat
glucos
instead
termin
xylos
moieti
found
prma
besid
higher
solubl
prm
varieti
interest
featur
microbicid
point
view
instanc
bock
viral
entri
siv
suscept
target
cell
also
prevent
dcsignmedi
captur
siv
subsequ
viru
transmiss
lymphocyt
compound
stabl
low
ph
day
ph
high
temperatur
day
also
spr
analysi
reveal
still
effici
bind
low
ph
stabil
low
ph
particular
import
microbicid
vagin
ph
acid
recent
alcian
blue
ab
phtalocyanin
deriv
also
describ
abl
bind
nlink
glycan
inhibit
infect
howev
current
unclear
sugar
specif
ab
whether
antivir
activ
also
base
multival
case
cba
describ
far
discoveri
smallsiz
nonpeptid
compound
abl
bind
nglycan
surfac
new
encourag
step
explor
type
chemotherapeut
investig
need
reveal
whether
compound
abl
block
infect
vivo
given
import
glycan
present
viral
envelop
affect
carbohydr
structur
andor
function
viral
envelop
accomplish
two
entir
differ
strategi
intracellular
interact
drug
glycosyl
machineri
virusinfect
cell
extracellular
interact
drug
lectin
innat
immun
system
glycan
present
viral
envelop
interf
cellular
glycosyl
pathway
might
compromis
hiv
envelop
glycosyl
aglucosidas
inhibitor
nbutyldeoxynojirimycin
nbdnj
block
remov
glucos
residu
glycan
prerequisit
trim
highmannos
type
glycan
structur
complextyp
glycan
nbdnj
demonstr
inhibitori
hiv
entri
recent
shown
encapsul
lysosom
significantli
increas
antivir
activ
nbdnj
nanomolar
rang
mannosidas
inhibitor
dmj
also
prevent
convers
highmannos
type
glycan
complex
type
glycan
block
enzymat
remov
mannos
residu
glycosidas
remov
glucos
residu
result
appear
higher
degre
highmannos
type
glycan
envelop
thu
dmj
act
synergist
cba
inhibit
infect
glycoyl
inhibitor
would
affect
glycan
synthesi
viral
glycoprotein
also
glycan
synthesi
cellular
glycoprotein
therefor
inhibitor
glycosidas
consid
potenti
medicin
treat
carbohydraterel
diseas
diabet
viral
infect
ie
influenza
viru
hiv
tumor
metastas
glycosyl
sphingolipid
gsl
storag
diseas
thu
iminosugar
consid
use
cancer
therapi
prevent
format
aberr
nlink
glycan
inhibit
catabol
glycosidas
order
stop
oncogenesi
tumor
metastasi
moreov
nbdnj
current
avail
zavesca
treatment
type
gaucher
diseas
autosomalrecess
inherit
defici
lysosom
enzym
bglucocerebrosidas
result
accumul
glycosylceramid
macrophag
gaucher
cell
thu
vivo
applic
glycosidas
inhibitor
seem
feasibl
goal
although
activ
nevertheless
interest
mention
antiinfluenza
drug
oseltamivir
tamiflu
zanamivir
relenza
drug
synthet
compound
bind
inhibit
activ
virusencod
sialic
acidbind
na
glycoprotein
abundantli
present
surfac
influenza
viru
whose
enzymat
activ
essenti
releas
viru
infect
cell
inhibit
na
result
inhibit
releas
progeni
influenza
virion
infect
cell
oseltamivir
also
zanamivir
global
use
treatment
influenza
viru
infect
besid
rare
case
seriou
side
effect
report
advers
effect
oseltamivir
nausea
vomit
zanamivir
diarrhea
thu
drug
interfer
interact
carbohydr
correspond
carbohydratebind
protein
use
medicin
multival
carbohydratecontain
agent
also
envis
attempt
prevent
pathogen
infectiontransmiss
target
dcsign
task
afford
specif
manner
interact
dcsign
block
multival
carbohydratecontain
drug
envelop
prevent
may
turn
compromis
effici
viru
transmiss
glycodendron
cover
mannosyl
oligosaccharid
shown
abl
inhibit
bind
dcsign
lower
nanomolar
rang
also
goldmannoglyconanoparticl
synthes
interact
dcsign
natur
densiti
oligosaccharid
link
goldnanoparticl
influenc
eventu
antivir
transmiss
activ
compound
hyperbranch
dendrit
polym
function
oligosaccharid
prove
also
abl
inhibit
viru
infect
blockag
dcsign
interact
viru
envelop
approach
interest
potenti
novel
carbohydratebas
antivir
inhibitori
select
particular
pathogen
ie
viru
still
await
valid
vivo
c
agent
recogn
glycan
viral
envelop
antivir
assay
evalu
antivir
properti
cba
sever
assay
exist
investig
whether
cba
peptid
nonpeptid
activ
envelop
virus
cell
free
viru
assay
hiv
ad
peripher
blood
mononuclear
primari
cell
pbmc
monocytemacrophag
varieti
cell
line
presenc
seri
dilut
cba
percentag
viral
inhibit
compound
determin
base
product
virusinduc
antigen
viral
rna
product
andor
determin
cytopathogen
effect
cocultiv
assay
also
perform
persist
lymhpocyt
uninfect
cell
order
determin
whether
compound
abl
inhibit
cellassoci
viral
transfer
dcsignexpress
cell
like
dcsignexpress
bcell
rajidcsign
primari
dc
cultur
often
use
studi
interact
dcsign
cocultiv
rajidcsign
cell
preexpos
noninfect
cell
mimic
transmiss
dcsign
cell
abovement
assay
give
inform
antivir
properti
cba
provid
clue
antivir
mechan
compound
timeofaddit
studi
use
determin
time
point
viru
lifecycl
block
inhibitor
investig
often
includ
surfac
plasmon
reson
studi
investig
direct
interactionaffin
cba
viral
envelop
glycoprotein
last
least
phenotyp
genotyp
resist
develop
viru
cba
cell
cultur
import
evalu
role
specif
glycan
recognit
cba
reveal
particular
pattern
glycan
configurationsdelet
drug
resist
develop
cba
could
accomplish
extracellular
approach
numer
report
alreadi
shown
cba
abl
effici
inhibit
entri
cellfre
hiv
particl
target
cell
also
prevent
giant
cell
format
take
place
hivinfect
uninfect
lymphocyt
cell
fuse
moreov
cba
may
also
prevent
hiv
migrat
genit
mucosa
block
interact
glycan
envelop
hiv
dcsign
carbohydr
receptor
dc
present
epithelia
genit
tract
final
demonstr
cba
also
prevent
transmiss
dcsigncaptur
virion
lymphocyt
therefor
cba
antivir
agent
known
far
act
four
import
differ
stage
hivinfectiontransmiss
process
fig
cba
bind
nlink
glycan
envelop
particl
well
present
surfac
hivinfect
cell
agent
need
enter
cell
exert
antivir
activ
lower
risk
cytotox
avoid
interact
cba
glycosyl
machineri
insid
cell
bind
cba
envelop
inhibit
viral
entri
stage
exact
mode
inhibit
still
unclear
leikina
et
al
report
ydefensin
retrocyclin
abl
inhibit
influenza
viru
infect
block
membran
fusion
mediat
viral
ha
crosslink
thu
immobil
membran
glycoprotein
retrocyclin
like
cba
multival
lectin
suggest
cba
might
work
similar
manner
retrocyclin
bind
induc
sever
conform
chang
necessari
abl
bind
coreceptor
insert
fusion
peptid
cell
membran
multival
bind
cba
could
affect
conform
chang
entri
effici
occur
anymor
research
need
reveal
exact
molecular
mechan
antivir
action
cba
escap
antivir
action
cba
delet
sever
nlink
glycan
viral
envelop
increas
cba
pressur
fig
sever
factor
affect
dynam
evolut
cba
resist
develop
one
cba
molecul
bind
sever
site
one
viral
envelop
molecul
highmannos
type
glycan
abundantli
present
sever
bind
option
cba
estim
prma
molecul
bind
time
one
singl
molecul
although
peptid
cba
hha
gna
cvn
bind
due
steric
hindranc
multipl
cba
delet
nglycan
may
creat
space
cba
molecul
bind
remain
glycan
mutat
glycoprotein
impli
delet
one
singl
nlink
glycan
would
suffici
viru
effici
escap
antivir
action
cba
fact
demonstr
multipl
oligosaccharid
delet
need
envelop
becom
phenotyp
resist
varieti
cba
includ
uda
prma
prm
consequ
high
genet
barrier
dual
patient
cba
therapi
therapi
includ
cba
may
develop
slow
drug
resist
cba
delet
glycan
may
creat
hole
protect
glycan
medicin
research
review
doi
shield
therebi
expos
hidden
epitop
immun
system
becom
vulner
neutral
antibodi
respons
fig
inde
shown
reitter
et
al
littl
two
glycan
delet
siv
dramat
increas
neutral
antibodi
respons
mutant
hivinfect
monkey
hu
et
al
prove
partli
deglycosyl
made
resist
cvn
becam
sensit
immunoglobulin
direct
part
envelop
sera
individu
sens
cba
may
repres
complet
new
mode
antivir
therapi
activ
involv
immun
system
attack
viru
virusinfect
cell
dual
principl
describ
antivir
compound
far
addit
cbabind
viral
envelop
might
opson
result
complement
activ
cellular
immun
respons
target
cba
regard
cba
act
complementari
mbl
nlink
glycan
serv
multipl
function
includ
afford
protein
stabil
resist
proteolyt
degrad
regul
enzym
activ
signal
glycan
synthesi
import
function
nlink
glycan
probabl
avoid
peptid
precipit
induc
correct
conform
newli
form
protein
endoplasm
reticulum
er
impli
would
limit
number
nlink
glycan
delet
order
escap
cba
drug
pressur
without
compromis
correct
fold
envelop
protein
incorrectli
fold
envelop
protein
expect
compromis
co
receptor
bind
fusion
addit
appear
oligosaccharid
may
indispens
replic
andor
infect
strain
select
increas
cba
pressur
nlink
glycan
never
found
delet
fig
among
complex
type
glycan
part
variabl
shown
delet
glycan
result
sever
impair
replic
capac
even
increas
suscept
inhibitori
effect
cba
futhermor
delet
highmannos
type
glycan
posit
seem
detriment
infect
would
therefor
interest
develop
antibodi
nlink
glycan
site
neutral
antibodi
specif
recogn
nglycan
epitop
recent
develop
antibodi
trimannos
structur
abl
recogn
siv
envelop
suggest
would
feasibl
goal
besid
cba
also
abl
prevent
viral
entri
sever
virus
contain
glycosyl
envelop
instanc
entri
hcv
pseudoparticl
cell
captur
dcsignexpress
cell
effici
block
plant
cba
gna
hha
ca
uda
nonpeptid
prma
cba
also
activ
infect
certain
virus
nidoviral
famili
like
coronavirus
arterivirus
torovirus
cmv
felin
immunodefici
viru
denv
infect
celltocel
transmiss
cvn
also
found
inhibitori
ebola
viru
influenza
viru
conflict
report
howev
exist
potenti
cba
inhibit
hsv
entri
bertaux
et
al
observ
antivir
activ
hha
gna
uda
prma
tiwari
et
al
show
entri
could
block
cvn
cvn
prma
preferenti
bind
extern
mannos
residu
rather
surpris
antivir
spectrum
would
differ
howev
oligosaccharid
present
viru
partli
depend
cell
line
produc
viru
case
fiv
shown
fiv
deriv
fibroblast
cell
line
crfk
remark
sensit
inhibitori
effect
plant
cba
fiv
deriv
thymocyt
cell
cultur
also
produc
insect
cell
tend
bind
cba
better
produc
mammalian
cho
cell
presum
higher
densiti
andor
amount
highmannos
type
oligosaccharid
insect
glycoprotein
therefor
import
investig
virus
deriv
natur
infect
cell
type
order
examin
interact
cba
thu
list
envelop
glycosyl
virus
inhibit
cba
certainli
limit
hiv
probabl
virus
sensit
cba
discov
context
cba
may
also
effect
pathogen
differ
virus
dcsign
act
univers
pathogen
receptor
capabl
bind
microorgan
like
tuberculosi
streptococcu
pneumonia
schistosoma
mansoni
whether
cba
also
abl
block
interact
pathogen
dcsign
still
need
investig
like
cba
interact
glycan
pathogen
prevent
bind
dcsign
therebi
compromis
dcsignmedi
transmiss
cba
favor
properti
microbicid
point
view
first
topic
microbicid
need
taken
cell
antivir
protect
lower
risk
cytotox
particular
agent
howev
care
taken
product
damag
cervic
epithelium
case
first
microbicid
test
larg
phase
iii
clinic
trial
second
plant
lectin
hha
gna
uda
nonpeptid
prma
prm
loos
antivir
activ
incub
ph
signific
relev
vagin
environ
acid
ph
due
product
lactic
acid
commens
lactobacilli
third
cba
abl
prevent
captur
dcsignexpress
cell
subsequ
transmiss
cell
dc
express
dcsign
resid
lamina
propria
vagin
epithelium
one
first
cell
encount
cross
epithelium
discuss
captur
transmiss
dcsign
repres
import
pathway
viral
dissemin
host
infect
effect
microbicid
abl
block
mode
transmiss
far
cba
seem
agent
demonstr
inhibit
dcsignmedi
viru
captur
transmiss
far
cba
enter
clinic
trial
use
microbicid
sever
first
gener
microbicid
candid
nonselect
target
includ
cellulos
sulfat
proven
either
toxic
andor
inact
clinic
trial
obviou
reason
almost
clinic
trial
current
ongo
conduct
antiretrovir
compound
alreadi
approv
clinic
use
inform
see
wwwavacorg
compound
predominantli
inhibitor
hivencod
revers
transcriptas
rt
act
viru
enter
suscept
target
cell
start
replic
recent
work
indic
combin
nonnucleosid
rtinhibitor
plant
lectin
hha
result
synergist
activ
hiv
observ
support
idea
cba
might
valuabl
new
entiti
microbicid
formul
vagin
environ
low
ph
creat
unfavor
barrier
potenti
invad
pathogen
includ
virus
hiv
acet
environ
establish
lactobacilli
belong
commens
flora
vagin
epithelium
besid
produc
lactic
acid
also
produc
h
antimicrobi
agent
cellular
surfac
howev
lactobacilli
contain
varieti
surfac
macromolecul
exopolysaccharid
glycoprotein
lipoteicho
acid
fimbriaepili
lectin
especi
latter
molecul
potenti
effector
function
inhibit
pathogen
commens
microorgan
also
thought
enhanc
epitheli
barrier
function
modul
immun
respons
surfac
molecul
recent
shown
commens
lactobacilli
could
engin
deliversecret
peptid
cba
thu
creat
perman
live
microbicid
vagin
environ
feasibl
approach
current
investig
creat
engin
commens
bacteria
ie
lactobacillu
jensenii
secret
cvn
modifi
lactobacilli
abl
grow
intravagin
mice
produc
cvn
concentr
least
ngml
vagin
wash
interplay
lectin
innat
immun
system
pathogen
extrem
complic
care
taken
administ
cba
antivir
agent
either
system
use
microbicid
cba
lectin
immun
system
interact
specif
glycan
envelop
glycoprotein
therefor
must
care
monitor
whether
cba
compromis
natur
defens
system
imped
bind
andor
interact
lectin
innat
immun
system
glycan
shield
nevertheless
develop
sever
mechan
abus
innat
immun
system
advantag
describ
hijack
ctype
lectin
dcsign
dcir
mmr
direct
transport
lymph
node
readili
infect
cell
possibl
protect
role
langerin
report
de
witt
et
al
also
consid
langerin
present
lc
propos
captur
hiv
follow
intracellular
destruct
demonstr
yet
whether
cba
interfer
viral
bind
langerin
addit
shown
take
advantag
complement
pathway
activ
mbl
bind
mbl
bind
trigger
lectin
pathway
lead
accumul
fragment
viral
surfac
induc
lytic
pathway
interact
complement
receptor
cr
host
cell
protect
lysi
complement
express
regul
complement
activ
cellular
membran
deriv
membran
host
cell
factor
also
present
viral
membran
protect
complement
lysi
moreov
opson
pathogen
complement
factor
like
normal
induc
clearanc
elimin
antigen
bind
crexpress
cell
howev
take
advantag
opson
bind
cr
infect
permiss
cell
like
monocyt
cell
dc
thu
although
innat
immun
system
repres
effici
firstlin
defens
invad
pathogen
case
seriou
shortcom
fail
effici
contain
infect
therefor
extern
cba
may
play
import
role
compens
shortcom
activ
select
cba
depend
glycan
specif
variabl
glycoform
synthesi
process
nlink
glycan
er
golgi
apparatu
glycosyltransferas
glycosidas
add
remov
monosaccharid
glycan
order
produc
glycoprotein
eventu
contain
highmannos
type
hybrid
type
complex
type
glycan
sever
factor
influenc
type
nlink
glycan
found
certain
glycosyl
site
includ
avail
quantiti
differ
glycosyltransferas
glycosidas
particular
cell
nucleotid
sugar
metabol
local
glycosyltransferas
within
subcompart
golgi
glycoprotein
protein
backbon
differ
type
nlink
glycan
call
glycoform
impli
celltyp
produc
particular
envelop
viru
may
influenc
activ
cba
viru
viru
might
exhibit
differ
glycosyl
pattern
envelop
glycoprotein
inde
fiv
produc
crfk
cell
cultur
highli
sensit
inhibitori
effect
sever
plant
lectin
fiv
deriv
thymocyt
cell
cultur
clearli
much
less
sensit
besid
variabl
glycoform
natur
lectin
also
determin
potenti
effici
bind
certain
glycoprotein
although
plant
lectin
antivir
activ
claim
determin
specif
highmannos
type
glycan
impli
share
exact
carbohydr
specif
instanc
gna
specif
oligom
hha
thought
show
specif
mannos
oligom
mention
prma
cvn
show
prefer
mannos
cvn
proven
activ
thu
although
first
glanc
sever
lectin
share
similar
carbohydratebind
specif
detail
studi
interact
carbohydr
often
reveal
slight
import
differ
sugar
affin
recent
plant
lectin
deriv
maiz
report
show
sequenc
similar
gna
although
lectin
share
amino
acid
sequenc
ident
conserv
amino
acid
predominantli
involv
conform
format
carbohydratebind
site
interestingli
gna
strongli
bind
highmannos
type
glycan
gna
maiz
almost
exclus
bind
complextyp
glycan
contain
residu
differ
carbohydr
specif
result
lower
antihiv
activ
gna
maiz
compar
gna
potenti
side
effect
cba
first
lectin
discov
year
ago
stillmark
observ
prepar
castor
bean
extract
agglutin
red
blood
cell
overview
see
call
agglutinin
due
abil
agglutin
red
blood
cell
nowaday
term
agglutinin
replac
lectin
carbohydratebind
protein
capabl
agglutin
besid
potenti
agglutin
red
blood
cell
sever
lectin
known
cytotox
inflammatori
anti
prolif
capac
highli
mitogen
induc
upregul
varieti
activ
marker
chemokin
andor
cytokin
phytohemagglutinin
pha
lectin
found
bean
mitogen
gener
use
stimul
cell
divis
microbicid
contain
cba
would
appli
intravagin
could
induc
inflamm
caus
lesion
epithelium
may
enhanc
chanc
infect
hiv
sexual
transmit
diseas
therefor
care
monitor
potenti
cytotox
side
effect
lectin
cba
gener
highli
warrant
mention
cvn
studi
great
detail
develop
microbicid
recent
studi
shown
cvn
effici
plant
lectin
pha
cona
express
stimul
activ
marker
hladr
lectinexpos
pbmc
induc
express
varieti
cytokineschemokin
interestingli
cba
mannosespecif
plant
lectin
hha
gna
glcnacspecif
plant
lectin
uda
smallsiz
nonpeptid
pradimicin
antibiot
show
hardli
effect
chemokinecytokin
product
observ
demonstr
cba
may
differ
biolog
activ
depend
natur
origin
thu
necessarili
harm
term
cell
activ
mitogen
activ
andor
cytokin
stimul
anoth
point
concern
develop
cba
potenti
microbicid
clinic
use
possibl
elicit
antibodi
although
cba
formul
microbicid
particular
highmolecularweight
agent
peptid
lectin
expect
significantli
systemat
absorb
exclud
tini
amount
taken
reach
blood
stream
induc
immun
respons
inde
shown
human
serum
contain
antibodi
dietari
lectin
mannosebind
banana
lectin
banlec
wga
garlic
allium
sativum
agglutinin
asa
result
indic
nonpeptid
lowmolecularweight
cba
may
prefer
peptid
lectin
system
microbicid
use
far
bacteri
plant
lectin
made
clinic
practic
treat
diseas
interestingli
oseltamivir
zanamivir
strongli
interact
envelop
na
influenza
gener
use
treatment
influenza
infect
except
rare
case
gener
seriou
side
effect
report
drug
carbohydr
sialic
acid
mimic
inhibit
interact
viral
na
acid
oligom
epitheli
receptor
cell
host
block
viru
releas
infect
cell
thu
mention
drug
block
interact
lectin
ie
na
host
carbohydr
safe
administr
human
final
possibl
crosslink
cba
cellular
glycoprotein
may
expect
occur
prevent
much
possibl
affect
function
glycoprotein
might
even
elicit
antibodi
selfepitop
vast
major
nlink
glycan
mammalian
glycoprotein
complextyp
glycan
cba
predomin
prefer
endstand
oligom
present
highmannos
type
glycan
like
prefer
mannosespecif
cba
conclus
caution
care
attent
given
choic
cba
would
select
pre
clinic
develop
taken
abovement
possibl
side
effect
account
clinic
import
issu
cba
qualifi
potenti
antivir
medicin
given
fact
cba
tightli
bind
glycan
envelop
virus
hiv
hcv
influenza
viru
corona
virus
other
number
uniqu
featur
discrimin
drug
cba
prevent
infect
target
cell
cellfre
viru
also
inhibit
syncytium
format
infect
cell
uninfect
cell
block
captur
viru
dcsign
mmrexpress
dendrit
macrophag
cell
prevent
subsequ
transmiss
viru
lymphocyt
moreov
multipl
cba
molecul
may
bind
one
singl
hiv
envelop
molecul
expect
endow
rather
high
genet
barrier
prove
display
broad
neutral
capac
wide
varieti
differ
viru
clade
howev
one
cautiou
extrapol
cell
cultur
data
vivo
situat
therefor
anim
model
includ
futur
studi
enabl
realist
estim
potenti
valu
approach
concern
inde
given
fact
cba
may
compet
lectin
innat
immun
system
andor
may
select
enough
discrimin
selfglycan
nonselfglycan
result
potenti
side
effect
howev
thorough
investig
varieti
peptid
prokaryot
plant
lectin
well
nonpeptid
cba
alreadi
shown
select
potenti
side
effect
mitogen
induct
differenti
marker
cytokin
chemokin
growth
factor
highli
depend
natur
sourc
cba
care
select
promis
cba
vivo
studi
therefor
warrant
take
antivir
neutral
properti
account
also
take
potenti
side
effect
immunogen
mitogen
crosslink
cellular
glycoprotein
ie
red
blood
cell
agglutin
interact
innat
immun
system
account
peptid
cba
probabl
importantli
synthet
nonpeptid
cba
repres
entir
new
class
antivir
target
glycan
shield
compromis
well
function
surviv
unfavor
environ
viru
although
investig
need
perform
clarifi
interactioncompetit
cba
natur
lectin
innat
immun
system
cba
antivir
compound
known
far
abl
block
infect
four
differ
way
direct
infect
cellcel
syncytia
format
captur
lectin
innat
immun
system
dcsign
mmr
transmiss
captur
viru
particl
cell
cba
pressur
viru
result
appear
mutant
viru
strain
glycan
delet
envelop
allow
immun
system
react
previous
cover
immunogen
epitop
concept
alreadi
proven
reitter
et
al
mutant
sivinfect
monkey
hu
et
al
mutant
virusinfect
cell
cultur
point
clinic
relev
approach
high
genet
barrier
cba
broad
neutral
capac
wide
varieti
hiv
strain
make
interest
new
class
antivir
system
microbicid
applic
although
cba
current
subject
clinic
applic
nevertheless
consid
interest
new
drug
candid
deserv
investig
